Tamoxifen and the endometrium.
Barakat
R R
RR
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
D000475:Alkenes / Q000009:adverse effects / Q000633:toxicity; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002277:Carcinoma / Q000139:chemically induced* / Q000453:epidemiology / Q000235:genetics / Q000473:pathology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000453:epidemiology / Q000235:genetics / Q000473:pathology / Q000517:prevention & control; D004717:Endometrium / Q000187:drug effects* / Q000473:pathology; D004965:Estrogen Antagonists / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D004967:Estrogens; D005260:Female; D011905:Genes, ras; D006801:Humans; D006965:Hyperplasia; D007890:Leiomyosarcoma / Q000139:chemically induced / Q000453:epidemiology; D008403:Mass Screening / Q000379:methods; D008593:Menopause; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009376:Neoplasms, Hormone-Dependent / Q000139:chemically induced* / Q000188:drug therapy / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control; D010636:Phenols / Q000009:adverse effects / Q000633:toxicity; D011127:Polyps / Q000139:chemically induced; D011960:Receptors, Estrogen / Q000187:drug effects; D012306:Risk; D013629:Tamoxifen / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
D000475:Alkenes; D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D004967:Estrogens; D010636:Phenols; D011960:Receptors, Estrogen; D013629:Tamoxifen; C090768:1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene